Alivus Life Sciences Ltd (formerly Glenmark Life Sciences) reported a robust performance for Q4 FY26, with a 66% year-on-year increase in net profit and steady revenue growth, reaching Rs. 689 crore. The company’s operating profit stood at Rs. 215 crore, maintaining healthy margins of 31%. Additionally, a final dividend of Rs. 5 per share has been recommended, reflecting improved operational strength and business momentum. Alivus caters to both regulated and emerging markets, enhancing its position in the growing Indian pharmaceutical sector, supported by rising global demand and government initiatives.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://tradebrains.in/alivus-life-sciences-takes-the-spotlight-after-66-yoy-profit-jump-in-q4-announces-5-final-dividend/
